Abstract
We report a female thalassaemia major patient who developed short stature and osteochondrodystrophic lesions during therapy with desferrioxamine (DFX). Healing was noted after the dose of DFX was decreased for 3 years. Unfortunately the spinal cartilage abnormalities did not change suggesting an irreversibility of the ossification process.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Deferoxamine / adverse effects*
-
Drug Hypersensitivity / etiology*
-
Female
-
Follow-Up Studies
-
Humans
-
Infant
-
Iron Chelating Agents / adverse effects*
-
Osteochondrodysplasias / chemically induced*
-
Time Factors
-
beta-Thalassemia / drug therapy*
Substances
-
Iron Chelating Agents
-
Deferoxamine